ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

2:00PM-3:30PM: Abstract Number: 0757

Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0734

Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases

Abstracts: Genetics, Genomics & Proteomics

2:00PM-3:30PM: Abstract Number: 0749

Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0779

Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

2:00PM-3:30PM: Abstract Number: 0784

Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

Abstracts: SLE – Treatment I: Renal

2:00PM-3:30PM: Abstract Number: 0762

Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0781

Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials

Abstracts: SLE – Treatment I: Renal

2:00PM-3:30PM: Abstract Number: 0739

Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

Abstracts: Epidemiology & Public Health I

2:00PM-3:30PM: Abstract Number: 0772

MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0750

Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0730

NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

2:00PM-3:30PM: Abstract Number: 0744

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus

Abstracts: Epidemiology & Public Health I

2:00PM-3:30PM: Abstract Number: 0770

Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0751

Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0740

Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease

Abstracts: Epidemiology & Public Health I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].